CalciMedica (CALC) Price & Analysis

Compare

265 Followers

CALC Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.43 - $5.97

Previous CloseN/A

Volume2.29K

Average Volume (3M)29.05K

Market Cap

$25.29M

Enterprise Value-$8.14M

Total Cash (Recent Filing)$24.63M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta0.59

Next Earnings

Aug 07, 2025

EPS Estimate

-0.35

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.36

Shares Outstanding13,971,990

10 Day Avg. Volume19,775

30 Day Avg. Volume29,048

Financial Highlights & Ratios

PEG Ratio0.13

Price to Book (P/B)0.25

Price to Sales (P/S)0.00

P/FCF Ratio-0.36

Enterprise Value/Market Cap-0.32

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit542.46

Enterprise Value/Ebitda0.09

Forecast

1Y Price Target

$16.00

Price Target Upside783.98% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

CalciMedica News

PremiumRatings

CalciMedica’s Strong Financial Position and Promising Clinical Pipeline Justify Buy Rating

2M ago

CALC

PremiumThe Fly

CalciMedica says cash sufficient to fund operating plan into mid-2026

3M ago

CALC

PremiumPre-Earnings

CALC Earnings this Week: How Will it Perform?

3M ago

CALC

PremiumRatings

Promising Phase 2 Results and Market Potential Drive Buy Rating for CalciMedica’s Auxora

3M ago

CALC

PremiumCompany Announcements

CalciMedica Highlights Auxora’s Potential in COVID-19 Treatment

3M ago

CALC

PremiumThe Fly

CalciMedica’s Auxora shows mortality reduction in COVID-19 pneumonia trial

3M ago

CALC

PremiumCompany Announcements

CalciMedica Announces Board Changes and New Appointment

5M ago

CALC

PremiumThe Fly

CalciMedica initiated with a Buy at Lucid Capital

6M ago

CALC

See All CALC News

See All News >

Bulls Say, Bears Say

Bulls Say

Clinical ValidationThe clinical benefits of Auxora, including the potential for reduced dialysis, mortality, and greater recovery of renal function, are expected to drive its adoption in the market.

Financial PerformanceCalciMedica announced 2024 full year financial results, posting EPS of ($1.22), compared to consensus of ($1.44).

Market OpportunityWith over 1 million patients in the AKI Auxora target market, there is anticipation of a significant market opportunity exceeding $10 billion.

Bears Say

EarningsCalciMedica announced 1Q25 financial results, posting EPS of ($0.36), compared to our estimate of ($0.33) and consensus of ($0.31).

Funding RequirementsThe company is planning to hold an EOP2 with the FDA and expects to initiate a Phase 3 study in acute pancreatitis by YE25, pending additional funding.

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

56.55% Insiders

3.00% Mutual Funds

22.84% Other Institutional Investors

15.10% Public Companies and Individual Investors

Detailed Ownership Overview >

CALC FAQ

What was CalciMedica’s price range in the past 12 months?

CalciMedica lowest stock price was $1.43 and its highest was $5.97 in the past 12 months.

What is CalciMedica’s market cap?

CalciMedica’s market cap is $25.29M.

When is CalciMedica’s upcoming earnings report date?

CalciMedica’s upcoming earnings report date is Aug 07, 2025 which is in 54 days.

How were CalciMedica’s earnings last quarter?

CalciMedica released its earnings results on May 14, 2025. The company reported -$0.36 earnings per share for the quarter, missing the consensus estimate of -$0.307 by -$0.053.

Is CalciMedica overvalued?

According to Wall Street analysts CalciMedica’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does CalciMedica pay dividends?

CalciMedica does not currently pay dividends.

What is CalciMedica’s EPS estimate?

CalciMedica’s EPS estimate is -0.35.

How many shares outstanding does CalciMedica have?

CalciMedica has 13,971,990 shares outstanding.

What happened to CalciMedica’s price movement after its last earnings report?

CalciMedica reported an EPS of -$0.36 in its last earnings report, missing expectations of -$0.307. Following the earnings report the stock price went down -1.036%.

Which hedge fund is a major shareholder of CalciMedica?

Currently, no hedge funds are holding shares in CALC

CalciMedica Stock Smart Score

Underperform

Fundamentals

Return on Equity

-134.15%

Trailing 12-Months

Asset Growth

-6.59%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

CalciMedica

CalciMedica (CALC) is a biotechnology company focused on the development of therapies to treat inflammatory and autoimmune diseases. The company specializes in targeting calcium release-activated calcium (CRAC) channels, which play a crucial role in the activation of immune cells. CalciMedica's lead product candidate is Auxora, a CRAC channel inhibitor designed to treat severe inflammatory diseases such as acute pancreatitis and COVID-19 pneumonia.

CALC Stock 12 Month Forecast

Average Price Target

$16.00

▲(783.98%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","17":"$17","4.25":"$4.25","8.5":"$8.5","12.75":"$12.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4.25,8.5,12.75,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2024","6":"Jul<br/>2024","9":"Nov<br/>2024","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.55,2.661538461538462,3.773076923076923,4.884615384615385,5.996153846153846,7.107692307692308,8.21923076923077,9.330769230769231,10.442307692307693,11.553846153846155,12.665384615384617,13.776923076923078,14.88846153846154,{"y":16,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.55,2.661538461538462,3.773076923076923,4.884615384615385,5.996153846153846,7.107692307692308,8.21923076923077,9.330769230769231,10.442307692307693,11.553846153846155,12.665384615384617,13.776923076923078,14.88846153846154,{"y":16,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.55,2.661538461538462,3.773076923076923,4.884615384615385,5.996153846153846,7.107692307692308,8.21923076923077,9.330769230769231,10.442307692307693,11.553846153846155,12.665384615384617,13.776923076923078,14.88846153846154,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.06,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.2,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.47,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.93,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.96,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.68,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.25,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.48,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.23,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.51,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.43,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.22,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.55,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >